Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: A retrospective study of routine clinical use (ANEMONE)

European Journal of Clinical Microbiology & Infectious Diseases

from Gastroenterology via xlomafota13 on Inoreader https://ift.tt/2BcnMEU
via IFTTT